Analyst Price Target is $42.00
▲ +147.35% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Opiant Pharmaceuticals in the last 3 months. The average price target is $42.00, with a high forecast of $42.00 and a low forecast of $42.00. The average price target represents a 147.35% upside from the last price of $16.98.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Opiant Pharmaceuticals.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.